LENS INCORPORATING MYOPIA CONTROL OPTICS AND MUSCARINIC AGENTS

• US 20140036225A1
• Filed: 07/31/2012
• Published: 02/06/2014
• Est. Priority Date: 07/31/2012
• Status: Active Grant

• Current Assignee: Johnson & Johnson Vision Care Incorporated (Johnson & Johnson)
• Original Assignee: Arthur H. Shedden Jr
• Inventors: Chehab, Khaled, Cheng, Xu, Shedden, Arthur H. Jr.
• Granted Patent: US 9,827,250 B2
• Time in Patent Office: Days
• US Class Current: 351/159.02
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/46 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/10 for accommodation disorders, e.g. myopia
• CPC Class Codes: G02C 2202/24 Myopia progression prevention
• CPC Class Codes: G02C 7/04 Contact lenses for the eyes disinfection or sterilisation of contact lenses A61L12/00
• CPC Class Codes: G02C 7/041 bifocal; multifocal

Abstract

Ophthalmic devices, such as contact lenses, may incorporate myopia control optics in combination with therapeutic agents also known to control myopia to create a drug delivery mechanism to inhibit or arrest the progression of myopia in individuals. Any number of contact lenses incorporating myopia control optics may be combined with a therapeutic agent such as atropine, atropine sulphate monohydrate, and/or pirenzepine

Claims

1. An ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression, the ophthalmic lens comprising:

a contact lens formed from a first material and incorporating myopia control optics; and

an antimuscarinic agent incorporated into a mixture being at least one of affixed to or incorporated into the first material forming the contact lens, the antimuscarinc agent being configured to elute into the eye over a predetermined period of time.

2. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, wherein the first material comprises a hydrogel.

3. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, wherein the first material comprises a silicon hydrogel.

4. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, wherein the antimuscarinic agent comprises atropine.

5. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, wherein the antimuscarinic agent comprises atropine sulphate.

6. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, wherein the antimuscarinic agent comprises pirenzepine.

7. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 4, wherein the antimuscarinic agent mixture comprises atropine dissolved in buffered saline solution.

8. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 5, wherein the antimuscarinic agent mixture comprises atropine sulphate dissolved in buffered saline solution.

9. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 6, wherein the antimuscarinic agent mixture comprises pirenzepine dissolved in buffered saline solution.

10. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, further comprises a photochromic agent incorporated into the contact lens.

11. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, further comprises a neutral filter dye incorporated into the contact lens.

12. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, wherein the contact lens comprises a daily wear lens.

13. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, wherein the contact lens comprises a reusable lens.

14. An ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression, the ophthalmic lens comprising:

a contact lens formed from a first material and incorporating myopia control optics; and

a dopamine agonists incorporated into a mixture being at least one of affixed to or incorporated into the first material forming the contact lens, the dopamine agonist being configured to elute into the eye over a predetermined period of time.